13951-70-7

Basic information

• Product Name: 11a,16b,17,21-Tetrahydroxy-pregna-1,4-diene-3,20-dione
• Synonyms: 11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione;16 Alpha Hydroxprednisolone;16A-HYDROXY-PREDNISONLONE;16α-HYDROXY-PREDNISONLONE;11,16a,17a,21-Tetrahydroxypregna-1,4-diene-3,20-dione;11β,16α,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione;11β,16α,17α,21-Tetrahydroxypregna-1,4-diene-3,20-dione;Einecs 237-731-1
• CAS NO: 13951-70-7
• Molecular Formula: C₂₁H₂₈O₆
• Molecular Weight: 376.44
• EINECS: 237-731-1
• Product Categories: Pharmaceutical Raw Materials;Intermediates & Fine Chemicals;Metabolites;Pharmaceuticals;Steroids;Metabolites & Impurities
• Mol File: 13951-70-7.mol
• Article Data: 15

Chemical Properties

• Melting Point: 235-238°C
• Boiling Point: 591.5 °C at 760 mmHg
• Flash Point: 325.6 °C
• Appearance: white crystalline solid
• Density: 1.381 g/cm³
• Vapor Pressure: 1.86E-16mmHg at 25°C
• Refractive Index: 1.629
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• PKA: 11.93±0.70(Predicted)
• Water Solubility: 815mg/L at 20℃
• CAS DataBase Reference: 11a,16b,17,21-Tetrahydroxy-pregna-1,4-diene-3,20-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 11a,16b,17,21-Tetrahydroxy-pregna-1,4-diene-3,20-dione(13951-70-7)
• EPA Substance Registry System: 11a,16b,17,21-Tetrahydroxy-pregna-1,4-diene-3,20-dione(13951-70-7)

Safety Data

• Hazardous Substances Data: 13951-70-7(Hazardous Substances Data)

Usage

Chemical Properties

White Crystalline Solid

Uses

Different sources of media describe the Uses of 13951-70-7 differently. You can refer to the following data:
1. A metabolite of Budesonide, an antiinflammatory agent
2. A metabolite of Budesonide (B689490), an antiinflammatory agent.
3. 11β,16α,17α,21-Tetrahydroxypregna-1,4-diene-3,20-dione (Budesonide EP Impurity A) is a metabolite of Budesonide (B689490), an anti-inflammatory agent.

InChI:InChI=1/C21H28O6/c1-19-6-5-12(23)7-11(19)3-4-13-14-8-16(25)21(27,17(26)10-22)20(14,2)9-15(24)18(13)19/h5-7,13-16,18,22,24-25,27H,3-4,8-10H2,1-2H3

Upstream product

• 1171-81-9 11β,16α,17,21-tetrahydroxy-pregn-4-ene-3,20-dione 
• 3044-42-6 21-acetoxy-11β-hydroxyl-1,4,16-pregnatriene-3,20-dione 
• 50-24-8 prednisolon 
• 64945-47-7 21-acetoxy-17α-hydroxy-11β-trifluoroacetoxy-1,4-pregnadiene-3,20-dione 
• 52-21-1 prednisolone 21-acetate 
• 37413-91-5 2-((10S,13S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate 
• 3103-17-1 17α-dehydroxyprednisolone 
• 98422-55-0 16α-21-diacetoxyprednisolone 
• 86401-80-1 11β,16α,17α,21-tetrahydroxypregnane-1,4-diene-3,20-dione-21-acetate 
• 91160-89-3 9α-bromo-11β,16α,17α,21-tetrahydroxypregnane-1,4-diene-3,20-dione-21-acetate 
• 77017-20-0 16α,17α,21-trihydroxypregna-1,4,9(11)-triene-3,20-dione-21-acetate 
• 37413-91-5 2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate 

Downstream Products

• 1195763-25-7 [23,23,24,24,25,25,25-2H7]-16α,17α-(butylidenedioxy)-11β,21-dihydroxypregna-1,4,23-triene-3,20-dione 
• 1105542-94-6 [22,23,23,24,24,25,25,25-2H8]-16α,17α-(butylidenedioxy)-11β,21-dihydroxypregna-1,4,23-triene-3,20-dione 
• 1185143-77-4 S-{[(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-8-(2-fluoro-4-methoxyphenyl)-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,9a,10,10a,10b,11,12-dodecahydro-6bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-6b-yl]carbonyl} dimethylthiocarbamate 
• 1185143-78-5 (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-8-(2-fluoro-4-methoxyphenyl)-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,9a,10,10a,10b,11,12-dodecahydro-6bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxole-6b-carboxylic acid 

Relevant articles and documents

Preparation method and application of 16, 17-dihydroxy steroid compound

The invention provides a preparation method and application of a 16, 17-dihydroxy steroid compound, and relates to the technical field of chemical synthesis. The method comprises the steps of: (a) reacting a compound shown as a formula I, lewis acid and an azole compound to obtain a compound shown as a formula II; and (b) reacting the compound as shown in the formula II, cyclic acyl peroxide and water, and then hydrolyzing under an alkaline condition to obtain a compound as shown in a formula III. Lewis acid and an azole compound are used in the dehydration reaction of the compound shown in the formula I, the operation is easy, the reaction conditions are mild, the energy cost is low, and the safety coefficient is high. The cyclic acyl peroxide is used in the oxidation reaction of the compound shown in the formula II, so that the method is good in atom economy, few in side reaction, free of excessive impurities, easy to implement and repeat, free of heavy metal participation, green, environment-friendly, safer and good in application prospect.

Preparation method of budesonide

The invention discloses a preparation method of budesonide, and belongs to the technical field of preparation and processing of medicines. According to the method, prednisolone acetate is used as an initial raw material, and is subjected to five steps of protection, dehydration, dihydroxy, hydrolysis and condensation to prepare the budesonide. According to the preparation method, the reaction process can be effectively shortened by improving the defects of a traditional process, reaction conditions are mild, osmium tetroxide which is high in toxicity and not environmentally friendly is avoided, environmental pollution is reduced, and the method is high in overall conversion rate, easy and convenient to operate, suitable for industrial production and wide in market prospect.

Preparation method of high-purity 16 alpha-hydroxyprednisolone

The invention discloses a preparation method of high-purity 16 alpha hydroxyl prednisolone, and belongs to the technical field of medicine preparation and processing. The method comprises the following steps: completely dissolving a 16 alpha hydroxyl prednisolone acetate crude product in a mixed solvent of dichloromethane and alcohol, adding an organic acid, dropwise adding a hypochlorite aqueoussolution, controlling the temperature to be 15-40 DEG C, carrying out a stirring reaction to obtain a primary treatment product, removing the impurity through a hydration refining method, and hydrolyzing to obtain the high-purity 16 alpha hydroxyl prednisolone. The method is simple to operate, mild in reaction condition and short in reaction route, the purity of the final product prepared by the method is higher than 99.5%, the content of the impurity H is lower than 0.02%, and the requirement of the market on high-purity 16 alpha hydroxyl prednisolone can be easily met.